| Amanda Andrade, DO | |
|
3126 S Jackson Ave Ste 200, Joplin, MO 64804-2500 | |
| (417) 208-3465 | |
| Not Available |
| Full Name | Amanda Andrade |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 13 Years |
| Location | 3126 S Jackson Ave Ste 200, Joplin, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528354008 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2017015138 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Integrity Home Care + Hospice | Springfield, MO | Home health agency |
| Phoenix Home Care | Springfield, MO | Home health agency |
| Mercy Hospital Joplin | Joplin, MO | Hospital |
| Mercy Hospital Carthage | Carthage, MO | Hospital |
| Mercy Specialty Hospital Southeast Kansas | Galena, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Clinic Joplin Llc | 0547300196 | 247 |
News Archive
The checkpoint inhibitor pembrolizumab (Keytruda) offers patients with advanced head and neck cancers longer survival time, according to a new global study led by Yale Cancer Center (YCC). The data was published today in the journal The Lancet.
One of the first large-scale genomic studies conducted in a developing country has discovered genetic variants that elevate the risk for skin lesions in people chronically exposed to arsenic. Genetic changes found near the enzyme for metabolizing the chemical into a less toxic form can significantly increase an individual's risk for developing arsenic-related disease.
Many kidney failure patients are increasing their chance of nerve damage in their legs and feet by simply having too much potassium in their diet, according to research carried out by the University of New South Wales (UNSW), the Prince of Wales Medical Research Institute (POWMRI) and the Prince of Wales Hospital.
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.
"With $2.5 trillion in mineral reserves, South Africa has the largest mining sector in the world," but "[t]he work can be devastatingly toxic for the body," with "inhumane and untenable" working conditions, Archbishop Desmond Tutu, archbishop emeritus of Cape Town, South Africa, writes in a Wall Street Journal opinion piece.
› Verified 2 days ago
| Entity Name | Mercy Clinic Joplin Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215264817 PECOS PAC ID: 0547300196 Enrollment ID: O20091218000092 |
News Archive
The checkpoint inhibitor pembrolizumab (Keytruda) offers patients with advanced head and neck cancers longer survival time, according to a new global study led by Yale Cancer Center (YCC). The data was published today in the journal The Lancet.
One of the first large-scale genomic studies conducted in a developing country has discovered genetic variants that elevate the risk for skin lesions in people chronically exposed to arsenic. Genetic changes found near the enzyme for metabolizing the chemical into a less toxic form can significantly increase an individual's risk for developing arsenic-related disease.
Many kidney failure patients are increasing their chance of nerve damage in their legs and feet by simply having too much potassium in their diet, according to research carried out by the University of New South Wales (UNSW), the Prince of Wales Medical Research Institute (POWMRI) and the Prince of Wales Hospital.
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.
"With $2.5 trillion in mineral reserves, South Africa has the largest mining sector in the world," but "[t]he work can be devastatingly toxic for the body," with "inhumane and untenable" working conditions, Archbishop Desmond Tutu, archbishop emeritus of Cape Town, South Africa, writes in a Wall Street Journal opinion piece.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amanda Andrade, DO 3126 S Jackson Ave, Ste 200, Joplin, MO 64804-2500 Ph: (417) 208-3465 | Amanda Andrade, DO 3126 S Jackson Ave Ste 200, Joplin, MO 64804-2500 Ph: (417) 208-3465 |
News Archive
The checkpoint inhibitor pembrolizumab (Keytruda) offers patients with advanced head and neck cancers longer survival time, according to a new global study led by Yale Cancer Center (YCC). The data was published today in the journal The Lancet.
One of the first large-scale genomic studies conducted in a developing country has discovered genetic variants that elevate the risk for skin lesions in people chronically exposed to arsenic. Genetic changes found near the enzyme for metabolizing the chemical into a less toxic form can significantly increase an individual's risk for developing arsenic-related disease.
Many kidney failure patients are increasing their chance of nerve damage in their legs and feet by simply having too much potassium in their diet, according to research carried out by the University of New South Wales (UNSW), the Prince of Wales Medical Research Institute (POWMRI) and the Prince of Wales Hospital.
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.
"With $2.5 trillion in mineral reserves, South Africa has the largest mining sector in the world," but "[t]he work can be devastatingly toxic for the body," with "inhumane and untenable" working conditions, Archbishop Desmond Tutu, archbishop emeritus of Cape Town, South Africa, writes in a Wall Street Journal opinion piece.
› Verified 2 days ago
Dr. Justin James Dillingham, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3126 S Jackson Ave, Ste 101, Joplin, MO 64804 Phone: 417-208-3465 | |
Michael D David, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1130 E 32nd St, Joplin, MO 64804 Phone: 417-347-2273 Fax: 417-347-2277 | |
Dr. Stephen Ray Thomas, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3202 Mcintosh Cir, Ste 302, Joplin, MO 64804 Phone: 417-347-8525 Fax: 417-347-8536 | |
Dennis Younker, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 702 E 34th St Ste 202, Joplin, MO 64804 Phone: 417-347-2535 Fax: 417-347-2553 | |
Dr. Maria Fe Fiel Bruce, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3126 S Jackson Ave, Suite 201, Joplin, MO 64804 Phone: 417-781-4727 Fax: 417-627-8727 | |
Shuruk Haib, M.D Family Medicine Medicare: Medicare Enrolled Practice Location: 2216 E 32nd St Ste 101, Joplin, MO 64804 Phone: 417-556-2780 Fax: 417-556-2781 | |
Dr. Noureddine El Moghrabi, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 100 Mercy Way, Joplin, MO 64804 Phone: 417-781-2727 |